术前放化疗±帕尼单抗后巩固化疗在潜在可手术局部晚期(IIIa期,N2+)非小细胞肺癌中的随机II期研究:NRG肿瘤学RTOG 0839
本研究为随机II期研究,评估在局部晚期非小细胞肺癌(NSCLC)患者中,术前同步放化疗(CRT)联合或不联合帕尼单抗后行手术及巩固化疗的疗效与安全性,主要终点为纵隔淋巴结灭菌率(MNS)。结果显示,CRT组与CRT+帕尼单抗组的MNS率分别为68.2%和50.0%(p=0.95),联合帕尼单抗未改善MNS,且帕尼单抗组出现意外的高死亡率。
要点
- CRT+帕尼单抗组MNS率为50.0%,CRT组为68.2%,两组无显著差异(p=0.95)。
- 帕尼单抗组发生4例5级不良事件(10.5%),CRT组无5级事件(0%)。
- 研究因无效性和实验组毒性过多提前终止,实际入组71例。
核心结论
- 在CRT基础上加用帕尼单抗未改善纵隔淋巴结灭菌率(MNS)。
- 帕尼单抗组出现意外的高死亡率,尽管与帕尼单抗的关系尚不明确。
- 对照组的结果与NRG Oncology RTOG 0229研究相似。
研究设计与样本
- 随机II期研究,2:1随机分配至CRT+帕尼单抗组或CRT组。
- 入组潜在可手术的局部晚期NSCLC患者,计划样本量97例,实际入组71例后因无效性和实验组毒性过多提前终止。
- 同步CRT方案:每周卡铂(AUC=2.0)、紫杉醇(50 mg/m2)和60 Gy放疗分30次。
- 帕尼单抗剂量为2.5 mg/kg每周一次,共6周。
- 巩固化疗:每周卡铂(AUC=6)和紫杉醇200 mg/m2每21天一次,共2周期。
主要发现
- 60例患者符合条件:CRT组19例(86%)和CRT+帕尼单抗组29例(76%)接受了手术。
- 术后毒性:CRT组3例4级不良事件(13.6%),0例5级(0%);CRT+帕尼单抗组6例4级(15.8%),4例5级(10.5%)。
- MNS率:CRT组68.2%(95%CI 45.1-86.1),CRT+帕尼单抗组50.0%(95%CI 33.4-66.6),p=0.95。
关键数值与推荐
- 研究设计旨在检测MNS从52%提高至72%。
- 使用0.15单侧I类错误和80%把握度,需要97例患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因无效性和实验组毒性过多提前终止,实际入组71例,未达到计划样本量97例。
- 帕尼单抗组死亡率意外升高,尽管与帕尼单抗的关系尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Multimodality therapy has curative potential in locally advanced NSCLC. Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology Radiation Therapy Oncology Group (RTOG) 0229 demonstrated the feasibility and efficacy of combining full-dose radiation (61.2 Gy) with chemotherapy followed by resection and chemotherapy. On the basis of that experience and evidence that EGFR antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in locally advanced NSCLC with a primary end point of MNS. METHODS: Patients with resectable locally advanced NSCLC were eligible if deemed suitable for trimodality therapy before treatment. Surgeons were required to demonstrate expertise after CRT and adhere to specific management guidelines. Concurrent CRT consisted of weekly carboplatin (area under the curve = 2.0), paclitaxel (50 mg/m2), and 60 Gy of radiation therapy delivered in 30 fractions. There was a 2:1 randomization in favor of panitumumab at 2.5 mg/kg weekly for 6 weeks. The mediastinum was pathologically reassessed before or at the time of resection. Consolidation chemotherapy was weekly carboplatin (area under the curve = 6) and paclitaxel, 200 mg/m2 every 21 days for two courses. The study was designed to detect an improvement in MNS from 52% to 72%. With use of a 0.15 one-sided type 1 error and 80% power, 97 patients were needed. RESULTS: The study was opened in November 2010 and closed in August 2015 by the Data Monitoring Committee after 71 patients had been accrued for futility and excessive toxicity in the experimental arm. A total of 60 patients were eligible: 19 patients (86%) who received CRT and 29 (76%) who received CRT plus panitumumab and underwent an operation. With regard to postoperative toxicity, there were three grade 4 adverse events (13.6%) and no grade 5 adverse events (0%) among those who received CRT versus six grade 4 (15.8%) and four grade 5 adverse events (10.5%) among those who received CRT plus panitumumab. The MNS rates were 68.2% (95% confidence interval: 45.1-86.1) and 50.0% (95% confidence interval: 33.4-66.6) for CRT and CRT plus panitumumab, respectively (p = 0.95). CONCLUSION: The addition of panitumumab to CRT did not improve MNS. There was an unexpectedly high mortality rate in the panitumumab arm, although the relationship to panitumumab is unclear. The control arm had outcomes similar to those in NRG Oncology RTOG 0229.
引用
- Edelman MJ, Hu C, Le QT, et al. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. J Thorac Oncol. 2017. PMID: 28629896. doi:10.1016/j.jtho.2017.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。